WMJ : official publication of the State Medical Society of Wisconsin
-
Little is known about how emergency physicians have used Wisconsin's Prescription Drug Monitoring Program (PDMP). ⋯ Although barriers exist, PDMP utilization appears useful to emergency physicians and associated with modifications to patient management.
-
Perioperative programs aimed at decreasing surgical stress to colorectal patients can reduce hospital length of stay and morbidity while improving the patient’s perception of the surgical experience. Our goal was to transform patient care from a perioperative platform based on individual physician and nurse choice to a standardized evidence-based Enhanced Recovery After Surgery (ERAS) protocol for all patients undergoing elective colorectal resections. ⋯ We implemented change through a new system of care based upon standardized evidence-based ERAS protocols through the preoperative, intraoperative, and postoperative patient experience. In the first year of the ERAS program, patients experienced a reduced length of stay without a significant difference in morbidity or mortality.
-
Neonatal resuscitations and significant adverse cardiorespiratory events during pediatric sedations are infrequent. Thus, it is challenging to maintain the skills necessary to manage patients experiencing these events. As the pediatric emergency medicine specialty expands, exposure of general emergency medicine physicians to these potentially critical patients may become even more limited. As such, effective training strategies need to be developed. Simulation provides the opportunity to experience a rare event in a safe learning environment, and has shown efficacy in skill acquisition for medical students and residents. Less is known regarding its use for faculty-level learners. ⋯ Emergency medicine faculty have limited opportunities to manage neonatal resuscitations and adverse events in pediatric sedations. Simulation training appears to be an effective educational modality to help maintain these important skills.
-
Case Reports
‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes. ⋯ Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.
-
Biography Historical Article
WPS Medical Director Helps Break Down Barriers to Advance Care Planning.